news-media/
18 pages · Updated September 7, 2026
Pages
- Events, congresses and meetings | Almirall
- Duaklir® will be available in the United States from 21st October | Almirall
- Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases | Almirall
- Almirall Exercises its Option with Dermira to License Rights to Lebrikizumab in Europe for atopic dermatitis | Almirall
- Ichnos Sciences and Almirall Enter into a Licensing Agreement for First-in-Class IL-1RAP Antagonist Monoclonal Antibody | Almirall
- Almirall licenses Aclidinium to Daewoong in Korea | Almirall
- Almirall and Microsoft announce partnership for digital transformation to enable the development of novel treatments for skin diseases | Almirall
- Almirall and Dermira Enter into Option and License Agreement for European Rights to Lebrikizumab | Almirall
- Almirall and Kaken Pharmaceutical enter into a license and distribution agreement for European rights to the topical formulation of efinaconazole | Almirall
- Almirall and Paratek enter into a License Agreement for Seysara® in China | Almirall
- Newsroom | Almirall
- Financial Results Q1 2026 | Almirall
- Almirall announces the initiation of a phase I study of anti-IL-1RAP first-in-class monoclonal antibody for autoimmune dermatological diseases | Almirall
- Almirall licenses an anti-IL-21 monoclonal antibody from Novo Nordisk to develop it as a first-in-class agent in dermatology | Almirall
- Almirall signs a pan-European licensing-in agreement with Ironwood for linaclotide, a novel gastrointestinal compound | Almirall
- Almirall meets 2025 guidance, delivering 12.4% net sales growth and continued pipeline progress | Almirall
- Almirall and GW announce European development and marketing agreement for Sativex® | Almirall
- Almirall and Simcere enter into a licensing agreement for IL-2-mu-Fc | Almirall